WO2001054676A2 - Formulations destinees a des etats de deshydratation - Google Patents

Formulations destinees a des etats de deshydratation Download PDF

Info

Publication number
WO2001054676A2
WO2001054676A2 PCT/EP2001/000863 EP0100863W WO0154676A2 WO 2001054676 A2 WO2001054676 A2 WO 2001054676A2 EP 0100863 W EP0100863 W EP 0100863W WO 0154676 A2 WO0154676 A2 WO 0154676A2
Authority
WO
WIPO (PCT)
Prior art keywords
creatine
formulations
dehydration
states
formulations according
Prior art date
Application number
PCT/EP2001/000863
Other languages
German (de)
English (en)
Other versions
WO2001054676A3 (fr
Inventor
Christian Gloxhuber
Bernd Mertschenk
Original Assignee
Degussa Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa Ag filed Critical Degussa Ag
Priority to AU2001244108A priority Critical patent/AU2001244108A1/en
Publication of WO2001054676A2 publication Critical patent/WO2001054676A2/fr
Publication of WO2001054676A3 publication Critical patent/WO2001054676A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to formulations in dehydration states.
  • Dehydration is generally understood to mean the decrease in body water, the amount of which in the average healthy adult accounts for 55-60% of the body's substance. Symptoms of dehydration are usually due to a disturbed renal, gastrointestinal, pulmonary or percutaneous water release without a corresponding balancing supply. Water loss is usually accompanied by significant sodium loss, which can lead to a serious and life-threatening lack of volume. The result is typically a general decrease in physical and mental performance.
  • the colloidal state of the protein in the body also changes, e.g. Because of the collapse, the ability to bind water decreases and the tissue turgor is reduced. The result is atrophic changes.
  • the main therapeutic aim is to replenish the body's fluid deposits by infusing Ringer's solutions of various compositions, which at least usually eliminates the acute lack of water.
  • the positive effect is lost after a short time and the old dehydrated state returns, which makes renewed infusions necessary. The actual cause of the dehydration symptoms is not eliminated with the previous measures.
  • the object of the present invention was therefore to provide formulations in the case of dehydration states which bring about better and more permanent water absorption into the body tissues and above all into the muscles.
  • the formulations according to the invention not only achieve better and increased water absorption in the different body tissues, but also that the water in the tissues is also stored significantly longer.
  • Creatine is a natural compound known as energy storage, especially in muscle tissue, which is not toxic, is catabolized by the kidneys to urinate creatinine and is generally well tolerated. Creatine is also known to bind 23 ml of water per gram (see Prof. Dr. Neumann, Institute for Applied Training Sciences at the University of Leipzig: Creatinabol Study). A number of studies have found that body weight increases when creatine is ingested, part of this weight gain being due to a significant increase in muscle mass; on the other hand, however, water is stored in a wide variety of tissues, an effect which, in addition to the also desirable increase in muscle mass, is of great benefit especially for the elderly.
  • creatine monohydrate but also physiologically compatible creatine salts such as creatine ascorbate and creatine pyruvate, which can of course also be present in any mixtures, have proven to be particularly suitable creatine compounds.
  • Methods for producing preferred creatine compounds are described in EP-A-075 4679, WO 98/381 83 and WO 98/28263.
  • infusion solutions and drinks tablets, capsules and powders have proven to be very advantageous in the treatment of dehydration symptoms.
  • Infusions and drinks are particularly suitable for successfully reversing acute dehydration symptoms in a short time.
  • the formulations according to the invention are preferably given in an amount which does not exceed a recommended daily dose of 4 g of creatine.
  • the upper limit of 4 g must be observed as the total daily dose, which must be taken into account in particular in the case of simultaneous administration of infusions containing creatine, the intake of creatine-containing drinks and the intake of solid creatine-containing formulations according to the invention.
  • the formulations according to the invention are preferably used in elderly patients with mostly reduced thirst perception and an associated, restricted hydration, in immobility patients who are subject to an increased reduction in muscle mass due to their restricted movement possibilities and in patients with impaired fluid absorption, so generally in patients who have increased dehydration symptoms.

Abstract

L'invention concerne des formulations destinées à des états de déshydratation, contenant de la créatine et/ou des dérivés de créatine tels que le monohydrate de créatine, l'ascorbate de créatine, et le pyruvate de créatine, ainsi que des mélanges de ces composés, dans une quantité telle que la composante créatine ne dépasse pas une dose quotidienne de 4 g de créatine. Ces formulations notamment administrées sous la forme de solutions d'infusion, de boissons, de comprimés, de gélules et de poudres, sont de préférence employées chez des patients souffrant d'états de déshydratation notamment dus à l'âge et/ou à l'immobilité, et/ou provoqués par des troubles d'assimilation de liquide. Les formulations selon l'invention peuvent également être employées dans le cadre d'une thérapie d'adjuvants dans des états de déshydratation. Ces formulations permettent d'une part d'améliorer et de renforcer l'assimilation d'eau dans les différents tissus corporels, et entraînent d'autre part une augmentation significative de la durée de stockage de l'eau de tissu.
PCT/EP2001/000863 2000-01-28 2001-01-26 Formulations destinees a des etats de deshydratation WO2001054676A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001244108A AU2001244108A1 (en) 2000-01-28 2001-01-26 Formulations for states of dehydration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10003835A DE10003835A1 (de) 2000-01-28 2000-01-28 Formulierungen bei Dehydratationszuständen
DE10003835.2 2000-01-28

Publications (2)

Publication Number Publication Date
WO2001054676A2 true WO2001054676A2 (fr) 2001-08-02
WO2001054676A3 WO2001054676A3 (fr) 2002-05-16

Family

ID=7629123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/000863 WO2001054676A2 (fr) 2000-01-28 2001-01-26 Formulations destinees a des etats de deshydratation

Country Status (3)

Country Link
AU (1) AU2001244108A1 (fr)
DE (1) DE10003835A1 (fr)
WO (1) WO2001054676A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688139A1 (fr) * 2000-09-14 2006-08-09 Board of Regents of the University of Nebraska Composés et formulations d'esters de créatine
US8703819B2 (en) 2007-01-31 2014-04-22 Alzchem Trostberg Gmbh Use of guanidinoacetic acid (salts) combination with betaine and/or choline to produced an agent that is beneficial to health
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
US10531680B2 (en) 2000-09-14 2020-01-14 Board Of Regents Of The University Of Nebraska Creatine ester pronutrient compounds and formulations

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10215007A1 (de) * 2002-04-05 2003-10-16 Degussa Bioactives Deutschland Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen
DE102004009962A1 (de) * 2004-03-01 2005-09-22 Degussa Ag Verwendung von Guanidin-Verbindungen als physiologisches Stärkungsmittel in Form von Nahrungsergänzungsmitteln, Futtermittelzusätzen, in kosmetischen Zubereitungen und als Pflanzenstärkungsmittel
SI1758463T1 (sl) 2004-06-09 2008-08-31 Alzchem Trostberg Gmbh Gvanidino ocetna kislina kot dodatek Ĺľivalski hrani
BR112020019467A2 (pt) 2018-03-27 2020-12-29 Evonik Operations Gmbh Uso de ácido guanidinoacético e/ou creatina em aquicultura

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014435A1 (fr) * 1990-03-19 1991-10-03 Brigham And Women's Hospital Traitement de troubles osmotiques a l'aide d'osmolytes organiques
US5397786A (en) * 1993-01-08 1995-03-14 Simone; Charles B. Rehydration drink
WO1998028263A1 (fr) * 1996-12-20 1998-07-02 Skw Trostberg Aktiengesellschaft Creatine pyruvates et leur procede de preparation
WO1998038183A1 (fr) * 1997-02-26 1998-09-03 Skw Trostberg Aktiengesellschaft Creatine-ascorbates et mode de preparation
DE19929994A1 (de) * 1998-07-09 2000-01-13 Sueddeutsche Kalkstickstoff Verwendung von Kreatin zur Behandlung von Dystrophien und Atrophien der Skelettmuskulatur
WO2000015187A1 (fr) * 1998-09-10 2000-03-23 Skw Trostberg Aktiengesellschaft Creatine et/ou derives de creatine utilises comme preparations cosmetiques contenant des agents de maintien d'humidification
WO2001003325A2 (fr) * 1999-06-30 2001-01-11 Skw Trostberg Aktiengesellschaft Utilisation de creatine ou de derives de creatine pour le traitement de troubles de l'etat de sante chez la femme

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014435A1 (fr) * 1990-03-19 1991-10-03 Brigham And Women's Hospital Traitement de troubles osmotiques a l'aide d'osmolytes organiques
US5397786A (en) * 1993-01-08 1995-03-14 Simone; Charles B. Rehydration drink
WO1998028263A1 (fr) * 1996-12-20 1998-07-02 Skw Trostberg Aktiengesellschaft Creatine pyruvates et leur procede de preparation
WO1998038183A1 (fr) * 1997-02-26 1998-09-03 Skw Trostberg Aktiengesellschaft Creatine-ascorbates et mode de preparation
DE19929994A1 (de) * 1998-07-09 2000-01-13 Sueddeutsche Kalkstickstoff Verwendung von Kreatin zur Behandlung von Dystrophien und Atrophien der Skelettmuskulatur
WO2000015187A1 (fr) * 1998-09-10 2000-03-23 Skw Trostberg Aktiengesellschaft Creatine et/ou derives de creatine utilises comme preparations cosmetiques contenant des agents de maintien d'humidification
WO2001003325A2 (fr) * 1999-06-30 2001-01-11 Skw Trostberg Aktiengesellschaft Utilisation de creatine ou de derives de creatine pour le traitement de troubles de l'etat de sante chez la femme

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688139A1 (fr) * 2000-09-14 2006-08-09 Board of Regents of the University of Nebraska Composés et formulations d'esters de créatine
US10531680B2 (en) 2000-09-14 2020-01-14 Board Of Regents Of The University Of Nebraska Creatine ester pronutrient compounds and formulations
US8703819B2 (en) 2007-01-31 2014-04-22 Alzchem Trostberg Gmbh Use of guanidinoacetic acid (salts) combination with betaine and/or choline to produced an agent that is beneficial to health
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism

Also Published As

Publication number Publication date
AU2001244108A1 (en) 2001-08-07
WO2001054676A3 (fr) 2002-05-16
DE10003835A1 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
DE69722401T2 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
DE4041283C2 (de) Blockierungsmittel der EDRF-Wirkung oder -Bildung für die Behandlung von Schockzuständen
JP4166951B2 (ja) 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
DE60027197T2 (de) Verwendung von ribose zur verhinderung von krämpfen und muskelkater
AT393221B (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
DE60125191T2 (de) Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion
WO2001054676A2 (fr) Formulations destinees a des etats de deshydratation
DE3011437A1 (de) Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen
DE60103055T2 (de) Nahrungsergänzung zur verbesserung des muskelenergiestoffwechsels, enthaltend alkanoyl-carnitine und ribose
DE19910682B4 (de) Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
WO2011141113A2 (fr) Combinaison de vitamine k et de nicotinamide
EP2931258B1 (fr) Compositions et solutions pour le lavage intestinal
WO2019201707A1 (fr) Mélange de substances comprenant du citrate de k-mg pour utilisation comme médicament
WO2015044180A1 (fr) Substance pour inhiber la calcification tissulaire, la fibrose tissulaire et des maladies liées au vieillissement
DE202010012256U1 (de) Abführmittel
WO2014087006A1 (fr) Procédé et dispositif d'administration de gaz hypoxique et hyperoxique
DE60020888T2 (de) Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust
DE3440140C2 (de) Verwendung von Thiamphenicol gegen die Gewöhnung an zentral wirkende Analgetika
EP2674159B1 (fr) Composition pharmaceutique pour la régénération du foie
DE102004008375B4 (de) Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege
DE10160485A1 (de) Verwendung von Kreatin und/oder einem seiner physiologisch geeigneten Derivate zur Prävention oder Linderung von nicht krankheitsbedingten Beeinträchtigungen und/oder Störungen der Muskelfunktion
EP0291751B1 (fr) Préparation pharmaceutique constituée par un mélange
EP1897450A1 (fr) Compositions contenant de l'acide lipoïde alpha
DE19929994A1 (de) Verwendung von Kreatin zur Behandlung von Dystrophien und Atrophien der Skelettmuskulatur
EP1563743B1 (fr) Composition comprenant une substance contenant de la caféine, en particulier guarana

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP